Estée Lauder Companies

▲ Bull Case

• ◆Beauty Reimagined Inflection Is Real and Quantified — EL has delivered three straight quarters of positive organic growth (Q1–Q3 FY26: +3%, +2%, +2%) with gross margin recovered to 76.4%, demonstrating credible path to FY27E EPS of $3.39 and FY28E of $4.11+, implying 2.5–3.0x EPS recovery over 24 months.
• ◆Fragrance + La Mer Are Durable Billion-Dollar Franchises — Jo Malone, Le Labo, Aerin, Tom Ford Beauty, and La Mer are collectively $2B+ revenue franchises with pricing power intact (demonstrated by 76% gross margin); channel expansion to Amazon Premium Beauty and TikTok Shop provides distribution leverage.
• ◆Lauder Family Control Ensures Long-Term Capital Allocation Discipline — Family controls 86% voting power through dual-class structure; de La Faverie and CFO Shrivastava demonstrated discipline (dividend cut 47%, buybacks suspended, capex down 40%), ensuring EPS recovery flows 1:1 to share-price recovery once normalized profitability is reestablished.

▼ Bear Case

• ◆Recovery Is Already Priced In at 30x FY26E P/E With Little Margin of Safety — At ~$91/share, EL trades ~30x consensus FY26E adj. EPS and ~27x FY27E, leaving no room for PRGP delivering <$800M–$1.0B or China growth stalling below +5%, potentially repricing to $65–70 (-23%) if execution falters.
• ◆China Prestige Beauty Has Not Yet Shown Absolute Growth Momentum — Q3 FY26 Greater China organic growth was likely flat-to-low-single-digit positive; if China growth remains capped at +2–3% sustainably (vs. consensus +5%), FY28 upside is severely constrained and stock trades on lower multiple.
• ◆Tom Ford, Dr.Jart+, and Too Faced Impairments Signal Portfolio-Management Failures That May Repeat — EL took $1.29B impairment in FY25 on three acquisitions; remaining ~$2B goodwill + intangibles means additional $300–500M impairment is plausible, reducing GAAP EPS and reigniting confidence crisis.

“Street consensus assumes EL achieves $800M–$1.0B in PRGP savings by FY27, China prestige recovery to +5% by FY27–FY28, operating margin normalization to 10–12% by FY28, and EPS recovery to $4.11 by FY28. The bullish variant argues management is being conservative on PRGP (50% upside to $1.2B+), China acceleration could reach +7–8%, and operating margin could hit 12–13%, pushing FY28 EPS to $4.80+ and fair value to $120+. The bearish variant argues PRGP delivers only $600M, China growth plateaus at +2–3% due to structural trade-down, and operating margin gets stuck at 8–9%, pushing FY28 EPS to $2.80 and fair value to $65–70. The market currently anchors to consensus, waiting for Q4 FY26 / Q1 FY27 data to determine which variant unfolds.”

• ◆FY27 Guidance Release (August 2026) — PRGP Run-Rate Proof Point; if disclosed savings ≥$500M run-rate, bulls win +10–15%; if <$400M or China guidance cut, bears win -15–20%.
• ◆Q4 FY26 / Q1 FY27 Earnings (Sept–Oct 2026) — Two Quarters of Sustained Organic Growth + Margin Proof; need +2–4% organic growth in both quarters and sustain 75%+ gross margin.
• ◆China Prestige Beauty Absolute-Growth Inflection (Q4 FY26 / Q1 FY27) — Greater China Segment Turns +4–5% YoY; if still flat-to-+2%, bear case (China capped +2–3%) gains credibility.
• ◆Fragrance + La Mer Segment Acceleration (ongoing quarterly) — Should grow +5–8% sustainably; if slows to +2–3%, signals competitive loss or pricing weakness undermining margin recovery.
• ◆Travel Retail Absolute Recovery (ongoing) — Hainan + Asian Airports Return to 80%+ of 2022 Levels; sequential acceleration provides upside, stalling provides downside.

• ◆China prestige beauty recovery stalls (absolute growth capped +1–2% vs. consensus +5%) — HIGH; FY28 EPS misses to $2.80; stock reprices to $65–70 (-28%); timing Q4 FY26 / Q1 FY27 earnings.
• ◆PRGP delivers $600M (vs. $800M–$1.0B guided) — HIGH; FY27 EPS lands $2.90; implies $70 fair value (-23%); timing FY27 initial guidance (Aug 2026).
• ◆Tom Ford Beauty or Dr.Jart+ face margin compression or additional impairment — MEDIUM; $300–500M charge; reignites confidence crisis even if adjusted earnings stable.
• ◆FX headwind accelerates (USD strength); reports -4–5pp revenue drag vs. -2pp modeled — MEDIUM; FY27 organic growth overstated vs. reported growth; -3–4% stock reaction.
• ◆De La Faverie execution stumble (personnel departure, strategy pivot, guidance cut) — MEDIUM; multiple compression to 22x on uncertainty; stock to $70–75.